Member Info for CauldStream7

Nlp; my previous post was meant for Tomozulu.
But as regards the cytokine storm that you mention, as an economist not pharmacist, I thought, perhaps in my ignorance, that Lupuzor/P140 was meant to achieve a reduction in autoimmune response to an invasive virus. That is why it is seen as relevant for alleviating various autoimmune diseases such as CIDP, Asthma, Crohn's as well as Lupus.

Not quite sure when you say that Lupuzor is not in the mix. How do you know?
If you read the Q and A session that was released on 9th April after the presentation by Tim McC on the 7th April, the answer to the question as to whether IMM was involved in the development of a vaccine was that it was involved in a consortium which is researching peptides to find a way of blocking the entry of the Covid virus into human cells. Finance for this research is coming from the French Govt. So I think that IMM is very much in the mix.
Does anyone know if IMM's P140 (Lupuzor) is being tested in the study announced today led by researchers at Edi Uni?

Thanks for link. Interesting.

In the near future any SP under 20p will look a bargain.
I'm sure you have noted today's news item that a research team from Edin Uni is testing 15 drugs on Covid-19 patients in intensive care with severe inflammation of the lungs. I wonder if Lupuzor or P140 in in the mix given the claims made by IMM for its effectiveness in treating inflammatory (autoimmune) diseases.

TM has to keep other investors happy too. I had not properly realised before these last 2 briefings by TM how much stuff is in the pipeline, mostly coming along to market ahead of Lupus Ph3. With regard to Lupus it could be really important to have the major US Lupus patient organisation onside as well as a group of key US lupus professionals.
I'm hoping for more frequent briefings from TM and other top IMM researchers to keep us abreast with developments. Those of us who have held IMM shares for years deserve to know.
Gone are the days when some wise guys on this and other chat spaces were sneering about IMM being a one trick pony!

No, the amount needed for Incanthera is £250,000 and the subscription can happen as late as October. So I don't see why Zimmer's new investment should not be for any other purposes than the ones stated in the RNS. In general the RNS seems to strengthen the case for investing in P140/Lupozor.

Although I feel optimistic about the future of Lupuzor I have greater expectations for the same peptide P140 for the treatment of other auto immune diseases like Crohns, Rheumatoid Arthritis and Asthma. Interestingly, anti malarial drugs which also used in Lupus treatment are being talked about for treatment of COVID-19. Might P140 be in the mix?
I feel that in a couple of years we'll all be looking back in disbelief that IMM's SP was once quoted in pence rather than in pounds!

Nolupus. I was not suggesting that GSK would be interested in IMM/Lupuzor. It is AZN that I believe could be interested.
As for the FDA, I agree with your views.

Nolupus: Intrigued at your mention of AZN. Since AZN's candidate to cure Lupus failed its Phase 3 trial last year, I've been expecting Britain's main rival to GSK to show interest in Lupuzor and IMM. Maybe it has and could this explain why TMC was so adamant that IMM did not need to seek additional funding at the end of 2019? Remember that if Lupuzor works it will damage Benlysta's sales and GSK's profits.
As for news of an accord with FDA, news on this was promised by the end of this quarter. It would damage IMM's credibility if this does not take place.

Small Trader, you raise a number of points. The one I wrote about concerning Sol is mainly what concerns me. As far as I know it does not require the approval of FDA because it is not a drug but a cosmetic to be used as a sun screen cream. It contains an active ingredient whick cures or prevents skin cancer and it already is approved for oral use.
So its appoval process is much shorter than drug trials - 18 months is the time estimated by Incanthera.
In the case of the approval process for Lupuzor, that is likely to be almost twice as long as Sol. As Nolupus has pointed out, the recruitment of patients for Phase 3 could take up to a year. After that there will be year of trials which will take from the date of the last patient to be enrolled.

Following my previous message, it might be a better idea than buying more IMM to take a more direct bet on Incanthera by buying their shares after the IPO.

It is only this week that I have realised that the Incanthera product called Sol on which it plans to spend the £2 million or so it hopes to raise from the IPO is not a drug but a cosmetic. It is intended to be a sun screen ointment with an active ingredient which can prevent sun-damaged skin from developing into skin cancer. Interestingly this active ingredient is approved for oral use against skin cancer.
The testing procedures required for the approval on a new cosmetic product are far less than required for a new drug and takes a much shorter period to complete before it can be marketed - anything from 18 tp 24 months.
Until now I could not see the rationale behind IMM's £2 million purchase of Incanthera shares in 2018; now I do. The sun screen market is very large (£12 billion annually) and growing and I feel sure that a new product that is shown to be effective in preventing skin cancer could be a WINNER. It won't take too long to find out.

I agree with your views on the SP .
IF the FDA agrees with IMM that the focus of the new Phase 3 should be on Lupus patients with the biomarker anti-dsDNA autoantibody positive I would feel confident that Lupuzor will reach its efficacy endpoint as happened with that same sub- group within the European cohort in the first Phase 3 trial. I would expect FDA approval to be very likely Maybe, too, the FDA will agree more specific measures of efficacy which will be helpful to IMM.

3 to 1 in favour of Buys today - similar to earlier days trading this month. Rising expectations of good times to come.

I find it strange that there have been 3 times more Buy orders than Sell - yet still the SP is lower than yesterday. I wonder why.

If I were Lanstead I would be drip-feeding Sell orders whenever the SP rises too much above 13p. I would do so until the contract period with IMM for increasing my payments in line the SP had expired.
I'm sure all small shareholders who are adding to their IMM holdings at the present low prices as their limited means allow will be profoundly grateful to me for my actions in extending the period of low-priced shares and enabling them to add to their IMM share holdings at no more than I paid.

leas - thanks for this info. I had not previously realised there was this destinction between the American patients and the Mauritian ones. I still find it very strange that the American patients who were on Lupuzor did not show a better outcome than those who were on SOC plus placebo. Even the IMM analysis of 28th May 2018 which showed the statistically significant favourable response of the European cohort which was treated with Lupuzor did not address the issue of the poor response in the American cohort who were on Lupuzor. And I have not come across any further info on the IMM website to indicate if further analysis has produced a scientific explanation for this strange resullt.
I hope the link with Avion will improve the selection of American patients for the new Phase 3 trial , and its supervision. Hopefully this will provide more realistic results than happened in the first Phase 3 trial.

leas - thanks for this info. I had not previously realised there was this destinction between the American patients and the Mauritian ones. I still find it very strange that the American patients who were on Lupuzor did not show a better outcome than those who were on SOC plus placebo. Even the IMM analysis of 28th May 2018 which showed the statistically significant favourable response of the European cohort which was treated with Lupuzor did not address the issue of the poor response in the American cohort who were on Lupuzor. And I have not come across any further info on the IMM website to indicate if further analysis has produced a scientific explanation for this strange resullt.
I hope the link with Avion will improve the selection of American patients for the new Phase 3 trial , and its supervision. Hopefully this will provide more realistic results than happened in the first Phase 3 trial.

I guess many shareholders will be thinking the same thought you have expressed about the SP coming very close to the Lanstead level. Only news about the new Phase 3 trial with parameters agreed with the FDA is likely to lift the price. And only if these parameters are close to what IMM desires - ie patients to be recruited must be Lupus Antibody Positive because it is in that group that there was a statistically significant response to Lupuzor in the previous Phase 3 trial. And they will also have to ensure that they now understand why the same group within the American cohort did not respond positively to Lupuzor.

I'm really not sure what news will provide a significant and lasting upward shift in the IMM share price. In the years before the start of the first IMM Phase 3 the SP oscillated between 40p and 60p for the great majority of the time, only occasionally moving outside that range.
We are now at a stage when another Phase 3 appears to be imminent and will be much better funded than the previous one. Moreover, from the analysis of the results of the first Phase 3, it failed to r each its endpoint as to efficacy because the results from the USA cohort were very strange, perhaps because they were conducted on a very small sample compared with the Europe one. Excluding the USA result, the Europe one showed a significant reduction in Lupus in Antibody Positive patients - and we would all have been celebrating had the USA patients cohort result not been so absurd.
With all the information we now have that the Patient Profile must be centred on Lupus Antibody Positive patients the prospects of the trial meeting its end points on efficacy and safety, I had supposed that the SP would at least reach the levels (40p - 60p) that it was at before the previous Phase 3. I guess that the cause of this is the scepticism that grips the investing community following the failure of the first Phase 3 which was preceded by bullish statements from the IMM chairman. Better if he had been more cautious in his prognostications.
But this time I think there is very strong case to be made out for Lupuzor's success in its next, much better funded, Phase 3.